enGene Therapeutics reported cash from operations of -$18.95M and free cash flow of -$18.95M for the quarter ended Jul 2026, up 26.2% year over year. This cash flow statement covers 16 quarters of results from Oct 2022 through Jul 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Oct2022 | Jan2023 | Apr2023 | Jul2023 | Oct2023 | Jan2024 | Apr2024 | Jul2024 | Oct2024 | Jan2025 | Apr2025 | Jul2025 | Oct2025 | Jan2026 | Apr2026 | Jul2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||
| Net Income | -7.42M | -5.28M | -4.72M | -82.50M | -10.71M | -14.98M | -14.15M | -15.30M | -24.62M | -25.82M | -28.99M | -37.88M | -29.75M | -30.23M | -32.50M | |
| Share-based Compensation | 1.58M | 0.02M | 0.04M | 0.04M | 3.35M | 3.29M | 3.98M | 5.53M | 1.66M | 9.07M | 9.05M | 30.10M | 2.61M | 12.08M | 45.20M | 29.70M |
| Gains from Investment Securities | 1.19M | 0.34M | -5.52M | -6.85M | ||||||||||||
| Cash from Operations | -6.22M | -4.44M | -7.30M | -6.78M | -7.37M | -14.16M | -7.18M | -19.57M | -25.70M | -22.95M | -25.66M | -24.94M | -28.90M | -30.50M | -18.95M | |
| Depreciation, Depletion & Amortization | ||||||||||||||||
| Amortizatization of Intangibles | 0.78M | 1.20M | 0.67M | 0.59M | 0.49M | 0.28M | ||||||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.05M | 0.04M | 0.04M | 0.07M | 0.08M | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M | 0.20M | 0.19M | 0.20M | 0.10M | |
| Change in Working Capital | ||||||||||||||||
| Change in Account Payables | 0.83M | 1.22M | -1.08M | -0.59M | 0.22M | -0.91M | 2.61M | -1.45M | 1.13M | -0.97M | 0.82M | 3.97M | -4.27M | -0.62M | 0.74M | |
| Change in Accured Expenses | -1.82M | -0.45M | 0.17M | 2.97M | 2.15M | 0.41M | 3.20M | -0.54M | -3.88M | 3.92M | -1.06M | 4.15M | 4.39M | -2.48M | 5.04M | |
| Other Working Capital Changes | 0.06M | 0.13M | 0.61M | -0.05M | 1.27M | 0.79M | 1.59M | 3.92M | -0.42M | 1.77M | -1.31M | -2.03M | 2.42M | 1.58M | -0.10M | |
| Investing Activities | ||||||||||||||||
| Capital Expenditures | 0.01M | 0.01M | 0.16M | 0.14M | 0.51M | 0.18M | 0.00M | 0.24M | 0.30M | 0.04M | 0.70M | 0.44M | 0.15M | 0.10M | ||
| Change in Acquisitions & Divestments | 10.00M | 31.75M | 46.76M | 48.69M | 43.04M | 73.95M | 72.50M | |||||||||
| Cash from Investing Activities | -0.01M | -0.01M | -0.16M | -0.14M | -0.51M | -0.18M | -0.00M | -125.27M | -84.96M | 17.95M | 1.38M | 40.50M | -126.30M | 23.64M | 30.12M | |
| Financing Activities | ||||||||||||||||
| Other financing activities | 56.88M | 60.15M | 0.00M | 0.20M | 0.03M | 1.99M | 126.25M | -103.00M | ||||||||
| Debt Issuance and Repayment | ||||||||||||||||
| Long-Term Debt Issuances | 30.00M | 22.50M | 25.00M | |||||||||||||
| Change in Capital Stock | ||||||||||||||||
| Net Shares Issued and Repurchased | 1.31M | 0.59M | 1.25M | 3.59M | 3.11M | 0.14M | 0.55M | 4.93M | 3.16M | |||||||
| Misc. | ||||||||||||||||
| Cash from Financing Activities | -0.01M | 7.76M | 27.55M | 50.84M | 12.00M | 193.50M | 0.05M | 60.16M | 0.00M | 0.20M | -0.67M | 1.99M | 141.66M | 0.07M | 0.02M | |
| Exchange Rate Effect | 0.00M | 0.00M | 0.00M | 0.00M | ||||||||||||
| Change in Cash | -6.25M | 3.31M | 20.10M | 43.93M | 4.12M | 179.16M | -7.13M | -84.67M | -110.66M | -4.80M | -24.92M | 17.53M | -13.54M | -6.79M | 11.20M | |
| Free Cash Flow | -6.24M | -4.45M | -7.46M | -6.91M | -7.88M | -14.34M | -7.18M | -19.81M | -26.00M | -22.99M | -26.36M | -25.38M | -29.06M | -30.60M | -18.95M | |
| Net Cash Flow | -6.25M | 3.31M | 20.10M | 43.93M | 4.12M | 179.16M | -7.13M | -84.67M | -110.66M | -4.80M | -24.95M | 17.55M | -13.54M | -6.79M | 11.20M |